Wire · opportunities
Merck and Isomorphic Labs Enter Strategic Research Collaboration
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
Merck and Isomorphic Labs have launched a strategic collaboration to use AI-driven drug design alongside Merck's proprietary data to discover new oncology small molecule candidates. Isomorphic Labs will handle AI-based molecular design while Merck manages development and commercialization.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Founders in AI drug discovery can expect growing collaboration models where AI teams supply molecular designs and pharma companies handle trials and sales. You need to position your tech as a critical innovation layer that pharma cannot easily replicate.
◆ Coverage
1 source · 20 Nov 2026
◆ Related on Wire
◆ Topics